

In the claims:

Please amend the claims, cancel claims and enter new claims as indicated below:

1-10 (canceled).

11 (currently amended). A pharmaceutical emulsion composition for parenteral delivery, said composition comprising, in combination:

- (a) a hydrophilic phase;
 - (b) from 2 to 40 percent volume per volume of a pharmacologically acceptable lipoid as a hydrophobic phase dispersed as particles in said hydrophilic phase;
 - (c) from 0.01 to 2 percent weight per volume of a retinide;
 - (d) from 0 to 10 percent volume per volume of a solvent;
 - (e) from 0.01 to 10 percent weight per volume of a non-ionic surfactant to stabilize said emulsion composition; ~~said surfactant selected from the group consisting of non-ionic surfactants and egg phospholipids;~~ and
 - (f) from 0 to 10 percent weight per volume of an isotonic agent;
- said emulsion composition having a pH of about 5 to 10.

12 (original). The composition of claim 11 wherein said retinide is fenretinide.

13 (original). The composition of claim 12 wherein fenretinide is present at about 0.1 to 0.5 percent weight per volume.

14 (original). The composition of claim 11 wherein the solvent is present in an amount of at least 0.01 percent volume per volume and is selected from the group consisting of ethanol, dimethylsulfoxamide (DMSO), and ethyl acetamide (DMA).

15 (original). The composition of claim 14 wherein the solvent is ethanol at about 0.01 to 5.0 percent volume per volume.

16 (original). The composition of claim 11 wherein the lipoid is selected from the group consisting of soybean oil, safflower oil, sunflower oil, borage oil, corn oil, olive oil, linseed oil, sesame oil, palm kernel oil, cotton seed oil, medium chain triglycerides from coconut oil distillates, black currant oil, and mixtures thereof.

17 (original). The composition of claim 16 wherein said lipoid is soybean oil at 10 to 30 percent volume per volume.

18 (currently amended). The composition of claim 11 wherein the non-ionic surfactant is selected from the group consisting of egg phospholipids, polyoxyethylene fatty acid esters, and block copolymers of polyoxypropylene and polyoxyethylene.

19 (currently amended). The composition of claim 18 wherein the non-ionic surfactant is egg phospholipid at about 2 percent weight per volume.

20 (original). The composition of claim 11 wherein the isotonic agent is present in an amount of about 1 to 3 percent weight per volume.

21 (original). The composition of claim 20 wherein the isotonic agent is glycerin at about 1 per cent weight per volume.

22 (original). The composition of claim 11 wherein the amount of retinide is about 0.1 to 0.5 percent weight per volume, the solvent is dehydrated ethanol at 0.0 to 5.0 percent volume per volume, the amount of said lipid is about 10 to 30 percent volume per volume, the amount of egg phospholipids is about 1 to 5 percent weight per volume, the isotonic agent is glycerin at about 1 percent weight per volume, and the pH is from 5.0 – 10.0.

23 (original). The composition of claim 1 wherein said particles are from 5 to 1000 nanometers in diameter.

24 (original). The composition of claim 23 wherein said particles are from 50 to 400 nanometers in diameter.

25 (original). A method of treating a hyperproliferative disorder in a subject in need thereof, comprising parenterally administering to said subject a composition according to claim 11 in an amount effective to treat said hyperproliferative disorder.

26 (original). The method of claim 25, further comprising the step of diluting said composition in an aqueous pharmaceutically acceptable carrier prior to said administering step.

27 (original). The method of claim 25, wherein said administering step is an intravenous administration step.

28 (original). The method of claim 25, wherein said subject is a human subject.

29 (previously presented). A pharmaceutical emulsion composition for parenteral delivery, said composition consisting essentially of, in combination:

(a) a hydrophilic phase;

(b) from 2 to 40 percent volume per volume of a pharmacologically acceptable lipid as a hydrophobic phase dispersed as particles in said hydrophilic phase,

wherein said lipid is selected from the group consisting of soybean oil, safflower oil, sunflower oil, borage oil, corn oil, olive oil, linseed oil, sesame oil, palm kernel oil, cotton seed oil, medium chain triglycerides from coconut oil distillates, black currant oil, and mixtures thereof,

and wherein said particles are from 5 to 1000 nanometers in diameter;

(c) from 0.01 to 2 percent weight per volume of fenretinide;

(d) from 0.01 to 10 percent volume per volume of a solvent selected from the group consisting of ethanol, dimethylsulfoxamide (DMSO), and ethyl acetamide (DMA);

(e) from 0.01 to 10 percent weight per volume of a surfactant to stabilize said emulsion composition; said surfactant selected from the group consisting of egg

phospholipids, polyoxyethylene fatty acid esters, and block copolymers of polyoxypropylene and polyoxyethylene; and

(f) from 0 to 10 percent weight per volume of an isotonic agent;
said emulsion composition having a pH of about 5 to 10.

30 (previously presented). The composition of claim 29 wherein fenretinide is present at about 0.1 to 0.5 percent weight per volume.

31 (previously presented). The composition of claim 29 wherein the solvent is ethanol at about 0.01 to 5.0 percent volume per volume.

32 (previously presented). The composition of claim 29 wherein said lipoid is soybean oil at 10 to 30 percent volume per volume.

33 (previously presented). The composition of claim 29 wherein the surfactant is egg phospholipid at about 2 percent weight per volume.

34 (previously presented). The composition of claim 29 wherein the isotonic agent is present in an amount of about 1 to 3 percent weight per volume.

35 (previously presented). The composition of claim 29 wherein the isotonic agent is glycerin at about 1 per cent weight per volume.

36 (previously presented). The composition of claim 23 wherein said particles are from 50 to 400 nanometers in diameter.

37 (previously presented). The composition of claim 29 wherein:
fenretinide is present at about 0.1 to 0.5 percent weight per volume;
the solvent is ethanol at about 0.01 to 5.0 percent volume per volume;
said lipoid is soybean oil at 10 to 30 percent volume per volume;
said surfactant is egg phospholipid at about 2 percent weight per volume;
said isotonic agent is glycerin and is present in an amount of about 1 to 3 percent weight per volume; and
said particles are from 50 to 400 nanometers in diameter.

38 (previously presented). A method of treating a hyperproliferative disorder in a subject in need thereof, comprising parenterally administering to said subject a composition according to claim 11 in an amount effective to treat said hyperproliferative disorder.

39 (previously presented). The method of claim 38, further comprising the step of diluting said composition in an aqueous pharmaceutically acceptable carrier prior to said administering step.

40 (previously presented). The method of claim 38, wherein said administering step is an intravenous administration step.

41 (previously presented). The method of claim 38, wherein said subject is a human subject.